Moderna Up 69% YTD on Cancer, Flu mRNA Pipeline; Adopts Xbow’s $1B Cybersecurity
Moderna has gained 69% this year on investor excitement around its mRNA-based cancer and flu vaccine pipeline compared with Pfizer’s lower-growth profile and 6.3% dividend yield. Separately, the company is strengthening IT security by adopting AI-driven cybersecurity from Xbow, which raised $120 million at a $1 billion valuation.
1. mRNA Pipeline and Stock Performance
Moderna’s mRNA-based cancer and seasonal influenza vaccine candidates have propelled shares 69% higher since the start of the year. Investors view the expanded pipeline as a key growth driver, contrasting with peers that offer dividends but more modest upside.
2. Partnership with Xbow for AI Security
Moderna has onboarded Xbow’s AI-driven cybersecurity services after Xbow secured $120 million in funding at a $1 billion valuation. The collaboration aims to safeguard application-level vulnerabilities as the company increases reliance on AI-generated code within its development workflows.